Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Ipamorelin vs Tesamorelin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Tesamorelin has stronger documented evidence (FDA-Approved) than Ipamorelin (Anecdotal + Phase 2) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, Tesamorelin is the safer pick. Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Ipamorelin

Anecdotal + Phase 2

Tesamorelin

FDA-Approved

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Used together in

Shared safety considerations

Both compounds share these reported concerns: injection site reactions. Open each peptide page for the full risk paragraph and source citations.

Side-by-side

Ipamorelin Tesamorelin
Class Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist GHRH analog (FDA-approved)
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion
Route SC injection SC injection
Half-life ~2 hrs ~26 min
Dosage (research) 200 mcg SC 2x daily (Seeds Vol 1 starting protocol, range up to 300 mcg 3x daily per r/Peptides wiki, often stacked with CJC-1295 no-DAC) 2 mg SC daily (FDA label)
Evidence tier Anecdotal + Phase 2 FDA-Approved
Research depth 64 indexed (PubMed 42 · CT 3 · EPMC 19) 127 indexed (PubMed 84 · CT 23 · EPMC 20)
Availability Compounding Restricted Prescription
Reported risks Mild fatigue; headache; injection site reactions; elevated IGF-1 theoretical Injection site reactions; hyperglycemia; joint pain; edema; elevated IGF-1

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Ipamorelin or Tesamorelin?

Tesamorelin has stronger documented evidence (FDA-Approved) than Ipamorelin (Anecdotal + Phase 2) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, Tesamorelin is the safer pick. Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between Ipamorelin and Tesamorelin?

Ipamorelin is classed as Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist; Tesamorelin is classed as GHRH analog (FDA-approved). Reported mechanism: Ipamorelin, Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise; Tesamorelin, Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion. Reported half-life: Ipamorelin, ~2 hrs; Tesamorelin, ~26 min. Routes in published studies: Ipamorelin, SC injection; Tesamorelin, SC injection.

Which has stronger evidence, Ipamorelin or Tesamorelin?

Tesamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Ipamorelin is graded Anecdotal + Phase 2, with 9 cited sources on its reference page and 64 indexed studies. Tesamorelin is graded FDA-Approved, with 13 cited sources on its reference page and 127 indexed studies.

Which is more accessible, Ipamorelin or Tesamorelin?

Tesamorelin is FDA-approved and Ipamorelin is not. Catalog status: Ipamorelin, Compounding Restricted; Tesamorelin, Prescription. FDA lists Ipamorelin in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).

Are Ipamorelin and Tesamorelin ever combined?

Yes. Fat Loss GH is a documented stack containing both Ipamorelin and Tesamorelin; the stack page gives the stated rationale.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…